Comprehensive modelling of multiple cell types reveals differences in Epo receptor signaling in primary erythroid and lung cancer cells
R Merkle, B Steiert, F Salopiata, S Depner, A Raue, C Kreutz, M Schelker, M Wäsch, ME Böhm, WD Lehmann, J Timmer, M Schilling, U Klingmüller · Pneumologie · 2015 · Heft 07
Bibliografische Angaben
Zusammenfassung
Lung cancer with its most prevalent form non-small-cell lung carcinoma (NSCLC) is one of the leading causes of cancer-related deaths worldwide and is commonly treated with chemotherapeutic drugs, e.g. cisplatin. Lung cancer patients frequently suffer from chemotherapy-induced anemia, which can be treated with erythropoietin (Epo). However, recent studies have indicated that Epo may not only induce erythropoiesis in hematopoietic cells but can also affect NSCLC cells. We demonstrate that the NSCLC cell line H838 expresses functional EpoR and treatment with Epo reduces cisplatin-induced apoptosis. To pinpoint diff…
